44
Participants
Start Date
September 10, 2024
Primary Completion Date
June 20, 2026
Study Completion Date
June 20, 2026
zagociguat 15mg
Once-daily oral tablets
zagociguat 30mg
Once-daily oral tablets
Placebo
Once-daily oral tablets
RECRUITING
Royal Melbourne Hospital, Melbourne
RECRUITING
Columbia University Irving Medical Center, New York
RECRUITING
Mount Sinai - Ichan School of Medicine, New York
ACTIVE_NOT_RECRUITING
UPMC Children's Hospital of Pittsburgh, Pittsburgh
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
WITHDRAWN
Children's National, Washington D.C.
RECRUITING
Neurologic Institute Carlo Besta of Milan, Milan
RECRUITING
Johns Hopkins University School of Medicine, Baltimore
RECRUITING
Rare Disease Research, Atlanta
RECRUITING
Akron Children's Hospital, Akron
RECRUITING
University Hospital Bonn, Bonn
RECRUITING
Mayo Clinic Rochester, Rochester
ACTIVE_NOT_RECRUITING
University of Pisa Neurological Clinic, Pisa
RECRUITING
Baylor College of Medicine, Houston
RECRUITING
University of Texas Medical School at Houston, Houston
RECRUITING
Children's Hospital of Colorado, Aurora
RECRUITING
Ludwig-Maximilians-University of Munich, Munich
RECRUITING
UC San Diego - Altman Clinical and Translational Research Institute, La Jolla
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Neuroscience Research Australia, Sydney
RECRUITING
Shared Health/University of Manitoba, Winnipeg
RECRUITING
McMaster University Medical Center, Hamilton
RECRUITING
Fondazione Policlinico Universitario Agostino Gemelli, Roma
RECRUITING
UCL Queen Square Institute of Neurology, London
RECRUITING
Newcastle University, Newcastle upon Tyne
Lead Sponsor
Tisento Therapeutics
INDUSTRY